AndreaBozzo/ceres-open-data-index huggingface dataset:
COVID-19 State Profile Report - Connecticut

<b>After over two years of public reporting, the State Profile Report will no longer be produced and distributed after February 2023. The final release was on February 23, 2023. We want to thank everyone who contributed to the design, production, and review of this report and we hope that it provided insight into the data trends throughout the COVID-19 pandemic.
Data about COVID-19 will continue to be updated at <a href='https://covid.cdc.gov/covid-data-tracker/#datatracker-home' >CDC’s COVID Data Tracker</a>.
 </b>

<p>
The State Profile Report (SPR) is generated by the Data Strategy and Execution Workgroup in the Joint Coordination Cell, in collaboration with the White House. It is managed by an interagency team with representatives from multiple agencies and offices (including the United States Department of Health and Human Services (HHS), the Centers for Disease Control and Prevention, the HHS Assistant Secretary for Preparedness and Response, and the Indian Health Service). The SPR provides easily interpretable information on key indicators for each state, down to the county level.
 </p>

It is a weekly snapshot in time that:
<ul>
<li>Focuses on recent outcomes in the last seven days and changes relative to the month prior</li>
<li>Provides additional contextual information at the county level for each state, and includes national level information</li>
<li>Supports rapid visual interpretation of results with color thresholds</li>
</ul>
CDC WONDER: Online Tuberculosis Information System (OTIS)

<p>The Online Tuberculosis Information System (OTIS) on CDC WONDER contains information on verified tuberculosis (TB) cases reported to the Centers for Disease Control and Prevention (CDC) by state health departments, the District of Columbia and Puerto Rico since 1993.  These data were extracted from the CDC national TB surveillance system.  OTIS reports case counts, incidence rates, population counts, percentage of cases that completed therapy within 1 year of diagnosis, and percentage of cases tested for drug susceptibility.  Data for 22 variables are included in the data set, including:  age groups, race / ethnicity, sex, vital status, year reported, state, metropolitan area, several patient risk factors, directly observed therapy, disease verification criteria and multi-drug resistant TB.   Each year these data are updated with an additional year of cases plus revisions to cases reported in previous years.   OTIS is produced by the U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention (CDC), National Center for HIV/AIDS, viral Hepatitis, STD and TB Prevention (NCHHSTP).</p>
Immunocytochemical evidence for co-expression of Type III IP

Background
          Taste receptor cells are responsible for transducing chemical stimuli into electrical signals that lead to the sense of taste. An important second messenger in taste transduction is IP3, which is involved in both bitter and sweet transduction pathways. Several components of the bitter transduction pathway have been identified, including the T2R/TRB taste receptors, phospholipase C β2, and the G protein subunits α-gustducin, β3, and γ13. However, the identity of the IP3 receptor subtype in this pathway is not known. In the present study we used immunocytochemistry on rodent taste tissue to identify the IP3 receptors expressed in taste cells and to examine taste bud expression patterns for IP3R3.
        
        
          Results
          Antibodies against Type I, II, and III IP3 receptors were tested on sections of rat and mouse circumvallate papillae. Robust cytoplasmic labeling for the Type III IP3 receptor (IP3R3) was found in a large subset of taste cells in both species. In contrast, little or no immunoreactivity was seen with antibodies against the Type I or Type II IP3 receptors. To investigate the potential role of IP3R3 in bitter taste transduction, we used double-label immunocytochemistry to determine whether IP3R3 is expressed in the same subset of cells expressing other bitter signaling components. IP3R3 immunoreactive taste cells were also immunoreactive for PLCβ2 and γ13. Alpha-gustducin immunoreactivity was present in a subset of IP3R3, PLCβ2, and γ13 positive cells.
        
        
          Conclusions
          IP3R3 is the dominant form of the IP3 receptor expressed in taste cells and our data suggest it plays an important role in bitter taste transduction.
2008 Mental Health National Outcome Measures (NOMS): CMHS Uniform Reporting System

Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for 2008. The URS is a state and national reporting system collected annually to support the Community Mental Health Services Block Grant program. State mental health authorities report on National Outcome Measures (NOMS), evidence-based practices, and utilization measures, providing an overview of state mental health delivery systems.
Patent AT-E400448-T1: [Translated] EMBOSSING FOIL AND SECURITY DOCUMENT

The invention concerns an embossing film, in particular a hot embossing film, including a transfer layer (7) arranged releasably on a carrier film (1), wherein the transfer layer (7) has at least one color layer (4) whose color appearance changes in dependence on a viewing angle, wherein the color layer contains colored interference pigments with a metal core. The invention further concerns a security document (8) produced using the embossing film.
Compound 530540: 4-Butylbenzoic acid, octadecyl ester

Chemical compound data from PubChem database. IUPAC Name: octadecyl 4-butylbenzoate. Molecular Formula: C29H50O2. Molecular Weight: 430.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 525885: N,N-Dimethyl-N'-(4-chlorophenyl)-pivalamidine

Chemical compound data from PubChem database. IUPAC Name: N'-(4-chlorophenyl)-N,N,2,2-tetramethylpropanimidamide. Molecular Formula: C13H19ClN2. Molecular Weight: 238.75. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Biomechanical Analysis of the Effects of Knee Savers on Knee Joint Loading During High Knee-Flexion Tasks

Occupational activities that require high knee flexion, such as kneeling and squatting, are associated with a higher prevalence of knee osteoarthritis (OA). It is generally accepted that excessive contact pressures in the joint may cause degeneration of healthy knee joints. Ailments in the patellofemoral (PF) joint were a common cause for knee pain in clinical observations. Knee savers have been used in sports and occupational activities to protect the knee joints during tasks involving high knee flexion. The biomechanics of the effects of knee savers on musculoskeletal loading have not been investigated. The purpose of the current study was two-fold: first was to develop a biomechanical model that accounts for the effects of the interface contact forces between thigh and leg, or between thigh-leg and knee savers; and second was to evaluate, using the biomechanical modeling, the effects of knee savers on musculoskeletal loading in the knee joint in high knee-flexion tasks. The biomechanical model was used to analyze the basic comfort and fitting tests of knee savers: the subjects to start from a standing posture, squat down to a working posture, and return to the standing posture, while subjects’ heels remained on the ground during the tasks. The tasks were repeated without and with knee savers. The musculoskeletal loadings in the knees were calculated using inverse dynamic modeling. Our results indicated that the wearing of knee savers in the high knee-flexion tasks helped to reduce the contact forces in the PF joint by about 20%. Our findings suggest that wearing knee savers may help reduce the risks of the knee OA for workers who are frequently required to perform high knee-flexion tasks for extended time.
MeSH 2025 Update - Update All Fields Report

<b>(Includes MeSH 2023 and 2024 changes)</b>  The MeSH 2025 Update - Update (All Fields) Report lists each individual modification made to a Descriptor or Supplementary Concept Record (SCR).  More than one field on a term can be modified during YEP, resulting in a term having multiple entries on the list.  <b>This report includes MeSH changes from previous years, starting from 2023.</b>
The new anti-actin agent dihydrohalichondramide reveals fenestrae-forming centers in hepatic endothelial cells

Background
          Liver sinusoidal endothelial cells (LSECs) react to different anti-actin agents by increasing their number of fenestrae. A new structure related to fenestrae formation could be observed when LSECs were treated with misakinolide. In this study, we investigated the effects of two new actin-binding agents on fenestrae dynamics. High-resolution microscopy, including immunocytochemistry and a combination of fluorescence- and scanning electron microscopy was applied.
        
        
          Results
          Halichondramide and dihydrohalichondramide disrupt microfilaments within 10 minutes and double the number of fenestrae in 30 minutes. Dihydrohalichondramide induces fenestrae-forming centers, whereas halichondramide only revealed fenestrae-forming centers without attached rows of fenestrae with increasing diameter. Correlative microscopy showed the absence of actin filaments (F-actin) in sieve plates and fenestrae-forming centers. Comparable experiments on umbilical vein endothelial cells and bone marrow sinusoidal endothelial cells revealed cell contraction without the appearance of fenestrae or fenestrae-forming centers.
        
        
          Conclusion
          (I) A comparison of all anti-actin agents tested so far, revealed that the only activity that misakinolide and dihydrohalichondramide have in common is their barbed end capping activity; (II) this activity seems to slow down the process of fenestrae formation to such extent that it becomes possible to resolve fenestrae-forming centers; (III) fenestrae formation resulting from microfilament disruption is probably unique to LSECs.
Research Article: BMC Medical Genetics

Background
          Narcolepsy is a common neuropsychiatric disorder characterized by increased daytime sleepiness, cataplexy and hypnagogic hallucinations. Deficiency of the hypocretin neurotransmitter system was shown to be involved in the pathogenesis of narcolepsy in animals and men. There are several hints that neurodegeneration of hypocretin producing neurons in the hypothalamus is the pathological correlate of narcolepsy. The ApoE4 allele is a major contributing factor to early-onset neuronal degeneration in Alzheimer disease and other neurodegenerative diseases as well.
        
        
          Methods
          To clarify whether the ApoE4 phenotype predisposes to narcolepsy or associates with an earlier disease onset, we have genotyped the ApoE gene in 103 patients with narcolepsy and 101 healthy controls.
        
        
          Results
          The frequency of the E4 allele of the ApoE gene was 11% in the patient and 15% in the control groups. Furthermore, the mean age of onset did not differ between the ApoE4+ and ApoE4- patient groups.
        
        
          Conclusion
          Our results exclude the ApoE4 allele as a major risk factor for narcolepsy.
Compound 526472: Pentyl perfluoroheptanoate

Chemical compound data from PubChem database. IUPAC Name: pentyl 2,2,3,3,4,4,5,5,6,6,7,7,7-tridecafluoroheptanoate. Molecular Formula: C12H11F13O2. Molecular Weight: 434.19. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E401652-T1: [Translated] SEALING CRACKS ON METAL DEVICES AS CONTAINERS FOR ACID AND RADIOACTIVE MATERIALS

The invention relates to the use of a composition comprising a chlorinated polyester resin in which the polyester satisfies formula (I) below: together with a crosslinking catalyst and a crosslinking accelerator in order to plug a crack affecting the wall of a metal device intended to contain a radioactive acid material. It is especially applicable in the maintenance of metal equipment of nuclear installations, in particular equipment that is for irradiated nuclear fuel reprocessing.
Emergency Temporary Shelters - Limited Stay Exits - By Shelter

Under <a href="https://chicityclerkelms.chicago.gov/Matter/?matterId=6DEAA6D8-D0E6-EE11-904C-001DD806E058" target="_blank">SO2024-0008386</a>, passed by City Council on 4/17/2024, the Department of Family and Support Services publishes data on the City-operated and City-funded emergency new arrivals shelters. This series of datasets contains data related to the <a href="https://www.chicago.gov/city/en/sites/texas-new-arrivals/home/faqs.html" target="_blank">Limited Stay Policy</a>. This dataset shows the total number of migrants who exited each shelter under this policy, each week.

<b>The first "week" listed (3/11/2024 to 5/5/2024) is actually cumulative since exits under the Limited Stay Policy began. All subsequent weeks will be individual weeks.</b>
Child Maltreatment 2016

This report presents national data about child abuse and neglect known to child protective services agencies in the United States during federal fiscal year 2016.

Letter from the Associate Commissioner

Acknowledgements

Summary

Chapter 1: Introduction

Chapter 2: Reports

Chapter 4: Fatalities

Chapter 5: Perpetrators

Chapter 6: Services

Appendix A: Required CAPTA Data Items

Appendix B: Glossary

Appendix C: State Characteristics

Appendix D: State Commentary

Metadata-only record linking to the original dataset. Open original dataset below.
Emergency Department Visits Involving Narcotic Pain Relievers

Describes emergency department (ED) visits involving the nonmedical use of  narcotic pain relievers (opioids) using data from the Drug Abuse Warning Network (DAWN). The drugs most commonly combined with narcotic pain relievers in ED visits; trends for narcotic pain relievers (2005-2011); demographic characteristics of narcotic pain reliever-related visits in 2011;  comparison of age groups, and trends for specific narcotic pain relievers by age group are analyzed.
Gadoterate meglumine

Gadoterate Meglumine is a gadolinium-based contrast agent used in magnetic resonance imaging (MRI) to enhance visibility of body structures. It's administered intravenously as a solution in various vial sizes, manufactured by Fresenius Kabi USA, LLC. This generic drug, approved under ANDA215304, helps diagnose conditions by improving MRI scans. This information was generated using AI and is provided for informational and research purposes only.
Patent AT-E400871-T1: [Translated] MULTIMODAL DATA ENTRY

The invention is directed to an apparatus for controlling at least one electronic device, comprising a haptic input means, an acoustic input means, and a switching means for switching between the acoustic input means and the haptic input means, such that an input is received by the apparatus via only one input means at a time. The invention is also directed to a method for inputting data using an apparatus comprising a haptic input means, an acoustic input means and a switching means for switching between the input means, comprising the steps of receiving input via one of the input means, switching from the one input means to the other input means upon receipt of a switching command by the switching means, and receiving input via the other input means wherein input is received by the apparatus via only one input means at a time. <IMAGE>
Compound 525675: p-Bromobenzylidene-propyl-amine

Chemical compound data from PubChem database. IUPAC Name: 1-(4-bromophenyl)-N-propylmethanimine. Molecular Formula: C10H12BrN. Molecular Weight: 226.11. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E400277-T1: [Translated] PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF DISEASES RELATED TO CELLULAR DISEASES OF THE BACKGROUND OF THE EYE

Chemical patent from PubChem database. Patent Number: AT-E400277-T1. Title: Method for Synthesizing Organic Compounds. Filing Date: 1995-11-28. Inventors: Patel, Amit, Jones, Michael. Abstract: A method for synthesizing organic compounds is disclosed, comprising reacting starting materials under specific conditions to yield the desired produc... IPC Classifications: C07K, A61K, G01N. This patent covers 14 claims related to 8 chemical compounds. Useful for intellectual property research, prior art searches, and chemical innovation tracking.
Compound 530037: 2-Ethyl-1,3-dimethylcyclopentane

Chemical compound data from PubChem database. IUPAC Name: 2-ethyl-1,3-dimethylcyclopentane. Molecular Formula: C9H18. Molecular Weight: 126.24. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 526729: 2-(2-(2-nonyloxy-ethoxy)-ethoxy)-ethanol, TFA

Chemical compound data from PubChem database. IUPAC Name: 2-[2-(2-nonoxyethoxy)ethoxy]ethyl 2,2,2-trifluoroacetate. Molecular Formula: C17H31F3O5. Molecular Weight: 372.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
NAAG Tobacco Settlement Payments

1999-2024. National Association of Attorneys General (NAAG). Policy—Tobacco Settlement Payments. The National Association of Attorneys General (NAAG) provides Tobacco Settlement Revenue data for 46 states participating in the Master Settlement Agreement (MSA) with the four largest tobacco companies in the United States.  Data are reported on an annual basis.  Four states (Florida, Minnesota, Mississippi, and Texas) provide the STATE System their Tobacco Settlement Revenue data independently.
Patent AT-E400135-T1: [Translated] MULTI-LAYER WRAPPED METHOD AND SYSTEM FOR PUSH CONTENT DATA METADATA

A method and system for nesting processing intelligence in a content delivery architecture having at least a first processing element (410) and a second processing element (510), the method comprising: creating a first envelope (614), said first envelope (614) comprising second processing element metadata (622), said second processing element metadata (622) adapted to be run on said second processing element (510); and forming a second envelope (610), said second envelope containing said first envelope (614) and first processing element metadata (612) adapted to be run on said first processing element (410).
Table 6. Illicit Drug Use Other Than Marijuana in the Past Month among Persons Aged 12 or Older, by State and Substate Regions: Percentages, Annual Averages Based on 2008, 2009, and 2010 NSDUHs

This table presents the 2008 to 2010 National Survey on Drug Use and Health (NSDUH) estimates of past month illicit drug use other than marijuana by those aged 12 or older by State and substate regions.
2012 Uniform Reporting System (URS) Tables for West Virginia

Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for 2012. The Uniform Reporting System (URS) is a state and national reporting system collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
Compound 527399: Tridec-10-en-2-yl acetate

Chemical compound data from PubChem database. IUPAC Name: tridec-10-en-2-yl acetate. Molecular Formula: C15H28O2. Molecular Weight: 240.38. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Schönlein-Henoch purpura during pregnancy with successful outcome for mother and newborn

Background
          Schönlein-Henoch purpura is a systemic vasculitis that affects vessels of a small caliber and rarely reported in the literature.
        
        
          Case presentation
          We report on a 35-year-old woman who developed palpable purpura with necrotizing cutaneous lesions on the lower limbs at 27 weeks of gestation. She also complained of epigastric pain and arthralgias. Histologic examination of a skin biopsy showed leukocytoclastic vasculitis with intravascular fibrin thrombi. The direct immunofluorescence analysis evidenced vascular deposits of IgA and C3 in the upper and mid-dermis. These findings were consistent with Schönlein-Henoch purpura. There was no evidence of renal involvement or placental dysfunction. The patient was treated with low-dose oral corticosteroids and a healthy infant was delivered by cesarean section. Examination of the placenta and the navel string disclosed no signs of vasculitis or infarction.
        
        
          Conclusions
          Schönlein-Henoch purpura is rarely reported in pregnancy. Treatment with orally administred corticosteroids may lead to a beneficial outcome for mother and newborn.
Probing the importance and potential roles of the binding of the PH-domain protein Boi1 to acidic phospholipids

Background
          The related proteins Boi1 and Boi2, which appear to promote polarized growth in S. cerevisiae, both contain a PH (pleckstrin homology) and an SH3 (src homology 3) domain. Previously, we gained evidence that a PH domain-bearing segment of Boi1, which we call Boi1-PH, is sufficient and necessary for function. In the current study, we investigate the binding of Boi1's PH domain to the acidic phospholipids PIP2 (phosphatidylinositol-4,5-bisphosphate) and PS (phosphatidylserine).
        
        
          Results
          Boi1-PH co-sediments with PS vesicles. It does so more readily when these vesicles contain a small amount of PIP2. Boi1-PH is degraded in yeast extracts in a manner that is stimulated by PIP2. Amino-acid substitutions that diminish binding to PIP2 and PS impair Boi1 function. Fusion to a myristoyl group-accepting sequence improves to different degrees the ability of these different mutant versions of Boi1-PH to function. Boi1 and Boi2 are localized to the periphery of buds during much of the budding cycle and to necks late in the cell cycle. Amino-acid substitutions that diminish binding to PIP2 and PS impair localization of Boi1 to the bud, but do not affect the localization of Boi1 to the neck. Conversely, a mutation in the SH3 domain prevents the localization of Boi1 to the neck, but does not impair localization to the bud.
        
        
          Conclusions
          Boi1's PH domain binds to acidic phospholipids, and this binding appears to be important for Boi1 function. The main role of binding to PS may simply be to promote the association of the PH domain with membrane. The higher-affinity binding to PIP2, which apparently promotes a conformational change in the PH domain, may play an important additional role. Boi1 and Boi2 are localized to sites of polarized growth. Whereas the SH3 domain is needed for localization of Boi1 to the neck, the phospholipid-binding portion of the PH domain is important for localization to the bud.